

Roche and UCB to present on Immunotoxins for Solid Tumour Therapy, Immunological Tolerance and Peptide Immunotherapy

This year's conference will explore the prediction and reduction of immunogenicity, clinical results and interpretations, along with optimising bioassays.

LONDON, ENGLAND, UNITED KINGDOM, June 3, 2015 /EINPresswire.com/ -- [Biopharmaceuticals](#) (BPs) represent a rapidly growing class of approved and investigational drug therapies that is contributing significantly to advancing treatment in multiple disease areas, including inflammatory and autoimmune diseases, genetic deficiencies, and cancer. Unfortunately, unwanted [immunogenic responses](#) to BPs, in particular those affecting clinical safety or efficacy, remain among the most common negative effects associated with this important class of drugs. To manage and reduce risk of unwanted [immunogenicity](#), diverse communities of clinicians, pharmaceutical industry, and academic scientists

are involved in: interpretation and management of clinical and biological outcomes of BP immunogenicity, improvement of methods for describing, predicting and mitigating immunogenicity risk, and elucidation of underlying causes.

(Source: 'Standardizing terms, definitions and concepts for describing and interpreting unwanted immunogenicity of biopharmaceuticals: Recommendations of the innovative medicines initiative ABIRISK consortium', 8 May 2015, NCBI)

Against this backdrop, SMi's 2nd annual Immunogenicity conference, taking place on the 29th and 30th June 2015 in London, will provide the ideal platform for the pharmaceutical industry, clinicians and academic scientists to align concepts and practices related to immunogenicity. The two-day conference programme will feature an array of case study driven presentations delivered by leading drug development teams, bioanalytical experts, and academics from companies including Apitope International NV, EpiVax, Inc, Roche Innovation Center Penzberg, Swedish Orphan Biovitrum and more. Unique perspectives will be shared on:

- Immunogenicity challenges in biologics development
- Tolerance induction techniques
- The latest in pre-clinical models
- Neutralising antibody assay best practice
- Updates on the ABIRISK project

Speaker Panel includes:

- Annie De Groot, CEO and CSO, EpiVax, Inc.
- Sandra Garcês, Rheumatologist Consultant and Researcher, Garcia de Orta's Hospital
- David Wraith, Chief Scientific Officer and Founder, Apitope International NV



- Margareta Wikén, Bioanalytical Manager, Swedish Orphan Biovitrum
- Morten Nielsen, Associate Professor, The Technical University of Denmark
- Gerhard Niederfellner, Head of Tumour Cell Biology, Pharma Research & Early Development, Roche Innovation Center Penzberg
- Chloé Ackaert, Postdoctoral Researcher, Cellular and Molecular Immunology, Free University of Brussels

To view the full speaker line-up and two-day conference programme, visit
<http://www.immuno.co.uk/einpresswire>

Vinh Trinh
SMi Group
+442078276140
[email us here](#)

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2016 IPD Group, Inc. All Right Reserved.